Lead Sponsor

Synta Pharmaceuticals Corp.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Must have histologically confirmed metastatic or unresectable malignancy with evidence of progression
•If subject has been treated with docetaxel, must have evidence of persistent or progressive disease
•Measurable disease per RECIST
•CNS metastases are permitted if treated and radiographically and clinically stable for 4 weeks prior to first dose
•ECOG status less than or equal to 2
•Life expectancy greater than 3 months
•Adequate hematological, hepatic and renal function as defined by protocol
•Willingness and ability to comply with study requirements
•Female subjects of childbearing age must have a negative pregnancy test at study entry
•Female subjects of child bearing age and males must agree to use adequate contraception as defined in the protocol

•Prior chemotherapy or investigational agents within 3 weeks or 5 times the agent's half life, whichever is shorter prior to first dose
•Radiotherapy within 2 weeks of first dose
•Surgery, radiotherapy or ablative procedure to the only area of measurable disease
•Major surgery within 4 weeks of first dose
•Poor venous access that would require an indwelling catheter for study drug administration
•History of severe allergic or hypersensitivity reactions to STA-9090 or docetaxel or their diluents or excipients
•Baseline QTc \>470 msec or previous history of QT prolongation while taking other medications
•Peripheral neuropathy \> Grade 1
•Ventricular ejection fraction less than or equal to 55% at baseline
•Treatment with chronic immunosuppressants. However subjects may receive steroids for stable CNS metastases
•Women who are pregnant or lactating
•Uncontrolled intercurrent illness